Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at 12th Annual Current Issues in Medicine, Biotech and Pharma Conference on September 18
September 16, 2014 11:20 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Sep 16, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ for potential use in bleeding...
Arch Therapeutics Announces Positive Preclinical Data From an Independent Study of AC5 Surgical Hemostatic Device(TM) in Animals on Blood Thinners
September 08, 2014 07:57 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Sep 8, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, announced that an independent...
Arch Therapeutics Will Present at the 2014 Aegis Capital Healthcare Conference in Las Vegas, NV September 10-13th, 2014
September 02, 2014 07:58 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Sep 2, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company") today announced it will be featured as a presenting company at the 2014 Aegis Capital...
Arch Therapeutics Will Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2014
August 26, 2014 07:58 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Aug 26, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), today announced it will be featured as a presenting company at the 16th Annual Rodman...
Arch Therapeutics Announces Positive Preclinical Data From Its Study of AC5 Surgical Hemostatic Device(TM) in Animals on Blood Thinner
August 25, 2014 07:58 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Aug 25, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ for potential use in bleeding...
Arch Therapeutics Announces Third Quarter 2014 Results
August 06, 2014 07:29 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Aug 6, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic...
Arch Therapeutics Announces Collaboration With University College Cork School of Pharmacy
July 22, 2014 08:30 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Jul 22, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, has entered into a new...
Arch Therapeutics Selects BSI as Its European Union Notified Body
July 15, 2014 08:30 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Jul 15, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™, a...
Arch Therapeutics Appoints Richard Davis as Chief Financial Officer
July 07, 2014 18:06 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Jul 7, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™, a...
Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at European Summit for Clinical Nanomedicine and Targeted Medicine in Basel, Switzerland on June 23
June 16, 2014 08:15 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Jun 16, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™, a...